Tazarotene Cream (0.1%) in Combination with Betamethasone

March 2005 | Volume 4 | Issue 2 | Case Reports | 228 | Copyright © March 2005

Valerate Foam (0.12%) for Plaque-type Psoriasis Sunil S. Dhawan MD, Marianna L. Blyumin MD, Daniel J. Pearce MD, Steven R. Feldman MD

A combination of multiple agents is often required to achieve treatment success for plaque-type psoriasis. We report a case series of 10 patients that were treated with betamethasone valerate foam (0.12%) in the morning and topical tazarotene cream (0.1%) in the evening for a total of 12 weeks or until plaques cleared. Erythema, scale, and thickness along with an aggregate severity score were determined at weeks 4, 8, and 12. One patient was lost to follow-up. Eight of the other 9 patients experienced improvement in their disease by week 12. Two patients were clear of their psoriasis at week 4 and 4 were clear at week 8. No adverse events, including irritation were reported; the use of the corticosteroid foam may protect against potential local irritation reported with tazarotene. The combination of tazarotene cream and betamethasone valerate foam is an effective combination approach to treating localized plaque-type psoriasis